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1536ABSTRACT
Background. Donation after circulatory death (DCD) is a solid resource to widen the
kidney donor pool. Italian activity has grown in the last years with encouraging results. Our
center has been active in DCD kidney transplantation (KTX) since November 2017,
providing 22.5% of Italian DCD donations in 2018. We present a single-center
retrospective analysis after a 1-year follow-up comparing DCD and donation after brain
death (DBD) KTX outcomes.
Methods. DCD (controlled only) and DBD KTX performed in our center from
November 2017 to December 2018 were considered. All DCDs underwent in situ
normothermic perfusion with extracorporeal membrane oxygenation, ex situ hypothermic
oxygenated perfusion, and renal biopsy prior to allocation.
We considered features of donors and recipients, immunosuppressive regimen, delayed
graft function (DGF), primary nonfunction (PNF), graft and patient survival (Kaplan-
Meier), creatinine, and estimated glomerular filtration rate at 1 year. Mean comparison
with a Student t test and with c2 test for frequencies were elaborated.
Results. Twenty-eight DBD, 18 double (64.3%) and 10 single (35.7%), were performed;
7 DCD, 3 double (42.8%) and 4 single (57.2%), were performed. By comparing single and
double KTX, no statistically significant difference was found. We recorded 7 DGFs (25%)
in DBD and 1 (14.3%) in the DCD group (P > .99) and no PNF. No graft was lost during
the first year. One-year estimated glomerular filtration rate (Chronic Kidney Disease
Epidemiology Collaboration) was, respectively, 62.7  25.3 and 54.71  14.66 mL/min
(P ¼ .25). DBD patient survival rate was 92.8%, DCD was 100%, and Kaplan-Meier
was not statistically significant (P ¼ .72).
Conclusions. Controlled DCD is a valid resource for KTX, with similar outcomes to
DBD. A multidisciplinary donor evaluation, combining clinical, perfusion, and histologic
data in the allocation process, allows excellent results.*Address correspondence to Giacomo Mori, University Hos-
pital do Modena, Via del Pozzo 71 41124, Modena, Italy. Tel: þ39
059 422 567; þ39 333 4814724; Fax þ39 059 422 4533. E-mail:
mori.giacomo@aou.itKIDNEY transplantation (KTX) is the best therapy forend-stage renal disease [1]. However, the number of
grafts procured per year is still insufficient to satisfy the
general demand, causing long waiting list times [2]. As a
consequence, donation after circulatory death (DCD) is
spreading across Europe due to donation after brain death
(DBD) organ shortage. Spain is the benchmark country with
18.4 pmp DCD kidney transplants (KTX) in 2018 [3]. Italian0
rg/10.1016/j.transproceed.2020.02.043experience in DCD is growing, after an initial reluctance
related to cardiac death declaration legislation, which re-
quires a minimum 20 minutes asystolia. DCD KTX nearlyª 2020 Elsevier Inc. All rights reserved.
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KIDNEY TRANSPLANTATION FROM DCD AND DBD 1537doubled last year, reaching 1.1 pmp (n ¼ 63; 42.1%
Maastricht II, 56.1%Maastricht III, and 1.8%Maastricht 4)
in 2018, with 22.5% of donors procured at our center [4].
Our DCD KTX protocol has been active since November
2017, with promising results [5]. According to the Emilia
Romagna regional policy, only controlled DCD (cDCD) are
considered, after informed consent and futile therapy
withdrawal in ICU patients (Maastricht class III) [6,7].
cDCD allows shorter warm ischemia time when compared
to donors with sudden cardiac arrest (uncontrolled DCD),
leading to significantly better outcomes. We present a
single-center retrospective analysis after 1 year of follow-up,
comparing results of KTX from DCD and DBD.MATERIALS AND METHODS
We compared all DCD and DBD KTX performed in the
Nephrology Unit of the University Hospital of Modena, Italy, from
November 2017 to December 2018. We excluded living donor
transplantation and combined liverekidney transplantation. Ac-
cording to Italian law, a minimum of 20 minutes of isoelectric
electrocardiogram must be recorded before cardiac death declara-
tion. In this protocol, only cDCD are considered. Every DCD un-
derwent in situ normothermic regional perfusion (extracorporeal
membrane oxygenation), followed by ex situ hypothermic oxygen-
ated perfusion (HOPE) by kidney assist to improve graft preser-
vation. Kidney biopsy was always performed to rule out irreversibleTable 1. Population
DBD Donor
Cause of Death
Head trauma 4
Ischemic stroke 3
Cerebral hemorrhage 14
Postanoxic encephalopathy 4
Mean age at Tx (years) 59.8  23.12
Waiting list (month)
Karpinski (mean)
Double: right kidney 3.8  0.9
Double: left kidney 4.4  1.1
Single 2.1  0.7
Cold ischemia time mean (hh:mm)
Double: right kidney
Double: left kidney
single
HLA mismatch
Mean creatinine (mg/dL)
First month
Third month
First year
Mean eGFR mL/min (CKD-EPI)
First month
Third month
First year
DGF, n (%)
PNF
Death (n)
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBD
graft function; eGFR, estimated glomerular filtration rate; PNF, primary nonfunction;acute damage (eg, thrombotic microangiopathy) and as allocation
criteria, according to Karpinski score (single KTX under 4 þ 4,
discard over 6 þ 6, double KTX in between). A maximum age of 70
years was accepted for DCD donors. In DBD, we performed kidney
biopsy only in expanded criteria donors (ECD), defined either as
subjects older than 65 years without comorbidities or younger but
with comorbidities, such as hypertension, cerebral stroke, or high
creatinine level (above 1.5 mg/dL). We report induction and
maintenance immunosuppressive therapy as well as donor/recipient
clinical and immunologic characteristics (age, cause of death,
ischemia time, HLA match; Table 1). KTX outcomes were: delayed
graft function (DGF), defined as the need for dialysis after KTX;
primary nonfunction (PNF); kidney function at discharge, at 1
month, and at 1 year after KTX; grafts; and patients survival.
Descriptive statistics are reported as mean and standard deviation
for continuous variables and frequency for categorical variables. A
comparison between data from DCD and DBD was performed with
a Student t test and with c2 test, and survival analysis was performed
according to Kaplan-Meier. A P lower than .05 was considered
significant.RESULTS
A total of 28 DBD KTX, 18 double (64.3%) and 10 single
(35.7%), were observed; 7 DCD KTX, 3 double (42.8%)
and 4 single (57.2%), were observed during the study. DBD
and DCD donors and recipients were homogeneous in
characteristics: mean age of DBD donors 59.8  23.12 yearsCharacteristics
DCD Donor DBD Recipient DCD Recipient
1
1
2
3
58.7  7.2 58.6  16.6 57.4  4.2
29.7  30.1 22.45  41.23
4.6  0.5
5  1
1.6  0.5
13:00  02:47 12:30  00:44
13:30  02:56 13:51  01:06
12:32  03:29 09:46  02:40
4  0.78 4.1  0.98
1.61  1.11 1.60  0.60
1.52  0.62 1.41  0.32
1.58  0.91 1.58  0.90
61  25.75 54.14  23.74
61.21  26.90 56  15.72
60.26  26.56 51.85  12.47
7(25%) 1 (14.3%)
0 0
2 0
, donation after brain death; DCD, donation after circulatory death; DGF, delayed
Tx, transplantation.
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7.2 years and DCD recipients 57.4  4.2 years; graft cold
ischemia time DBD (double right/left 13:00  02:47/13:30
 02:56; single 12:32  03:29) and DCD (double right/left
12:30  00:44/13:51  01:06; single 09:46  02:40); donor/
recipient HLA mismatch DBD 4  0.78, DCD 4.1  0.98.
All DCD donors and 64.3% of DBD donors underwent
kidney biopsy (see Table 1 for Karpinski score). All DCD
recipients received induction immunosuppression with
antithymocyte immunoglobulins (aTG). In DBD KTX,
antithymocyte immunoglobulins accounted for 50% of the
patients (sensitized recipients, ECD), while anti-interleukin-
2 receptor monoclonal antibodies (basiliximab) were
administered to the other half (standard recipients). Main-
tenance immunosuppression consisted of steroids, tacroli-
mus, and mycophenolic acid. For DCD KTX, HOPE
solution blood gases and biochemistry were monitored every
15 minutes to assess organ function. Mean lactate dehy-
drogenase values of 360.2  363.2 IU/L at the beginning
and 455.6  233.1 IU/L at the end of perfusion were
detected on the HOPE solution; lactates were 0.7  0.2
mmol/L initially and 0.8  0.4 mmol/L at the end of
perfusion. No graft was discarded after extracorporeal
membrane oxygenation and HOPE. By comparing the re-
sults from DBD and DCD KTX, no statistically significant
difference was found. We recorded 7 DGFs (25%) in the
DBD KTX and 1 (14.3%) in the DCD (P > .99). There was
no PNFs in either group. Hospital stay was similar in days:
18  15 DBD and 14.6  0.47 DCD (P ¼ .45). After 1 year
of follow-up, mean serum creatinine resulted in 1.54  0.79
mg/dL in DBD and 1.43  0.31 mg/dL in DCD (P ¼ .3);
estimated glomerular filtration rate (calculated with
Chronic Kidney Disease Epidemiology Collaboration for-
mula) was, respectively, 62.7  25.3 and 54.71  14.66 mL/
min (P ¼ .25). We stratified both groups in single and
double KTX, and still no statistical difference resulted.
Survival analysis did not show any death-censored graft loss
in the first year, although 2 DBD recipients died (1 circu-
latory arrest, 1 sepsis). Thus, patient survival was 92.8% for
the DBD group and 100% for the DCD group (P ¼ .72).
DISCUSSION
Our experience describes comparable results for DBD and
cDCD KTX. No statistically significant difference was
demonstrated in terms of renal function or survival rate
after 1 year of follow-up. DGF and PNF rates were excel-
lent, as was estimated glomerular filtration rate. A multi-
disciplinary evaluation of donors, short ischemia times
(thanks to the Emilia Romagna organs allocation network),and the use of the Karpinski score granted outcomes not
inferior to DBD KTX outcomes. Lactate dehydrogenase
and lactic acid measurements during machine perfusion did
not raise any concern on graft quality; thus, no graft was
discarded after HOPE. The single transplantation rate was
not reduced by DCD donation, therefore highlighting the
screened organs’ quality and the regional procurement sys-
tem’s efficiency. Double KTX seems a solid strategy to
ensure good results when using ECD. The satisfying results
found in the DCD group are partly due to slightly inferior
mean age of donors and standard deviation (although not
statistically significant when compared to DBD) and the
uncontrolled DCD exclusion from our protocol. A small
sample size is the main limit of this study.CONCLUSIONS
No significant difference in terms of outcomes was
described between cDCD and DBD KTX after 1 year of
follow-up. cDCD was confirmed to be a viable resource to
expand the donor pool. Optimal results can be reached with
a multidisciplinary donor evaluation, combining clinical,
perfusion, and histologic data in the allocation process.
Further experience is needed to support ECD DCD
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